JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation
Status unconfirmed · Phase 1
Conditions studied: MYELODYSPLASTIC SYNDROME; MDS, ACUTE MYELOID LEUKEMIA; AML
In brief
This is a Phase 1a/b study to evaluate the safety and tolerability of an antibody conditioning regimen known as JSP191, in combination with low dose radiation and fludarabine, in subjects with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) undergoing allogenic blood stem cell transplantation.
Key facts
- Study ID
- NCT04429191
- Run by
- Jasper Therapeutics, Inc.
- People needed
- 40
- Starts
- 2020-07-08
- Expected to finish
- 2023-12-08
- Last updated by the study team
- 2021-06-11
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- City of Hope Comprehensive Cancer Center — Duarte, California, United States (enrolling)
- Stanford University — Stanford, California, United States (enrolling)
- Rush University Medical Center — Chicago, Illinois, United States (enrolling)
- Oregon Health & Science University — Portland, Oregon, United States (enrolling)
- Huntsman Cancer Institute - University of Utah — Salt Lake City, Utah, United States (enrolling)
- Fred Hutchinson Cancer Research Center — Seattle, Washington, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.